Literature DB >> 20148910

Association of FcGRIIa with Graves' disease: a potential role for dysregulated autoantibody clearance in disease onset/progression.

Kadija Yesmin1, Chantal Hargreaves, Paul R Newby, Oliver J Brand, Joanne M Heward, Jayne A Franklyn, Stephen C L Gough, Matthew J Simmonds.   

Abstract

OBJECTIVE: Although autoantibody production is a key feature of autoimmunity, it is not known whether variation in autoantibody production and clearance pathways is involved in disease susceptibility. The Fc Gamma Receptor IIa (FcGRIIa) molecule is involved in the clearance of autoantibodies and a functional single nucleotide polymorphism (SNP), rs1801274, which has been shown to alter autoantibody clearance, has been associated with a number of autoimmune diseases (AIDs) including systemic lupus erythematosus and type 1 diabetes. This study aimed to determine whether FcGRIIa is associated with Graves' disease (GD) in the UK Caucasian population by Tag SNP screening common polymorphisms within the FcGRIIa region.
DESIGN: A case control association study investigating nine Tag SNPs within FcGRIIa, which captured the majority of known common variation within this gene region. PATIENTS: A dataset comprising 2504 UK Caucasian GD patients and 2784 geographically matched controls taken from the 1958 British Birth cohort. MEASUREMENTS: We used the chi(2)-test to investigate association between the Tag SNPs and GD.
RESULTS: Association between the rs1801274 (P = 0.003, OR = 1.12 [95% CI = 1.03-1.22] and rs6427598 (P = 0.012, OR = 0.90 [95% CI = 0.83-0.98]) SNPs and GD was observed. No other SNPs showed association with GD. No associations were seen between any of the SNPs investigated and specific GD clinical phenotypes.
CONCLUSIONS: This study suggests that variation in FcGRIIa predisposes to GD and further supports the role of FcGRIIa as a susceptibility locus for AIDs in general.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148910     DOI: 10.1111/j.1365-2265.2010.03780.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Immunogenetic mechanisms leading to thyroid autoimmunity: recent advances in identifying susceptibility genes and regions.

Authors:  Oliver J Brand; Stephen C L Gough
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

2.  Association of FCGR2A rs1801274 polymorphism with susceptibility to autoimmune diseases: A meta-analysis.

Authors:  Chang'e Zhang; Wenju Wang; Hong'e Zhang; Lulu Wei; Shuping Guo
Journal:  Oncotarget       Date:  2016-06-28

3.  Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

Authors:  Salvatore Siena; Eric Van Cutsem; Mingyu Li; Ulf Jungnelius; Alfredo Romano; Robert Beck; Katia Bencardino; Maria Elena Elez; Hans Prenen; Mireia Sanchis; Andrea Sartore-Bianchi; Sabine Tejpar; Anita Gandhi; Tao Shi; Josep Tabernero
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

4.  Implication of VDR Rs7975232 and FCGR2A Rs1801274 Gene Polymorphisms in the Risk and the Prognosis of autoimmune Thyroid Diseases in the Tunisian Population.

Authors:  S Mestiri; I Zaaber; I Nasr; H Marmouch
Journal:  Balkan J Med Genet       Date:  2020-08-26       Impact factor: 0.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.